MYCN and neuroblastoma: We have previously shown that transgenic mice co-expressing an active ALKF1174L mutation with MYCN via the tyrosine hydroxylase promoter potentiates neuroblastoma development characterized by earlier onset, higher penetrance and enhanced lethality (Berry et al., 2012).